Coinbase CEO Brian Armstrong: Organizing an Enhanced Cognition Dinner
Brian Armstrong announced a dinner next month in Boston, inviting scientists and engineers from the fields of neuroscience, genetics, drug development, computational biology, or machine learning to discuss how to safely enhance human intelligence. The topics will also cover treatments for cognitive disorders and ways to help healthy adults learn faster, reason better, and solve more difficult problems.
He emphasized that there are still many unknowns: which paths are feasible, which are safe, especially for effective solutions for adults. If a suitable founding team emerges from the discussions, he intends to provide funding support. Those unable to attend in person can join online, with travel expenses reimbursable, and registration can be done through the application link he published.
This continues his recent practice of using dinners to facilitate biotech startups. He has self-funded the research paper platform ResearchHub and co-founded NewLimit, which focuses on epigenetic reprogramming to delay aging. Previously, he hosted a dinner on embryo editing in the Bay Area, stating that approximately 400 million people worldwide are affected by genetic diseases, and expressed willingness to invest if a team is formed. In public interviews, he has discussed nutrients and child development, as well as whether therapies should be applied to level cognitive baselines, stating that humanity needs to master its own evolution as artificial intelligence becomes stronger.
The dinner places treatment and enhancement at the same table, clearly leaning towards interventions that can be effective in adults, rather than only discussing embryos or children. The participation threshold is relevant frontline work or expertise, rather than an open roadshow.
In market mechanisms, this is a founder selection market: the buyers are scientists looking to form teams, and the sellers are crypto-rich individuals willing to cover travel expenses and commit checks. Funds have not yet entered the new company, but will first go towards airfare and one night of interdisciplinary dialogue. Beneficiaries are laboratories lacking startup capital but having hypotheses for adult cognitive interventions; the pressured parties are traditional pharmaceutical companies that view enhancement as an ethical no-go zone. The event is driven by a public call, not by drug applications.
Cognition is being written as an investable infrastructure, placed alongside exchanges on the same personal balance sheet.
Source: Public Information
ABAB AI Insight
Armstrong is transforming Coinbase's cash flow into a source for biotech projects: ResearchHub is changing scientific publishing, NewLimit is changing cellular aging, and the dinner is changing the team formation mechanism. The embryo editing dinner has already tried the phrase "the U.S. should have a defining company"; this time, the focus shifts from disease prevention to adult cognitive enhancement, effectively expanding the indications from patients to healthy individuals. The AI race is the public time pressure he has given—when machines become smarter, should humans change their baseline.
The capital path is that the dinner serves as a seed round pre-screening: reimbursing travel lowers the friction of attendance, and the application form acts as the first layer of filtering, allowing for on-site assessment of whether interdisciplinary collaboration can yield a founding team, with checks coming from his personal account rather than Coinbase's main business. The motivation is to occupy the category of "safe enhancement," which currently lacks a standard company. Resource mobilization relies on reputation, airfare, and a table, rather than building a lab.
The analogy falls on talent harvesting similar to Thiel Fellow, and the Silicon Valley tradition of inventing companies over dinner; NewLimit has already proven his willingness to turn the challenging path of epigenetics into a fundable entity. The industry phase is shifting from the longevity trend of cellular reprogramming to the more sensitive cognitive layer. The focus is not on already listed psychiatric drugs, but on whether the plasticity of the adult brain can be recognized as a druggable target.
The structural judgment belongs to the precondition of technological substitution: using drugs, genes, and computational biology to replace the old path of "only relying on education to build intelligence." The mechanism is: treatment and enhancement share targets; once adult interventions are proven safe, indications will expand from medical records to performance; regulation and ethics will lag behind the teams already formed at the dinner. Whoever first writes safety boundaries into trial designs will take the definition rights.
ABAB News · Cognitive Law
The dinner is a pre-screening for checks, not socializing.
Once treatment is established, indications will slide towards enhancement.
As machines become smarter, human baselines will become an investable category.